// App-Quantinova.ai

e16516 : Patient outcomes following disease progression with enfortumab-vedotin (EV) in metastatic urothelial carcinoma (mUC).

Researchers

Presenter

  • Mohammed Ateeb Khan

Principal Investigators

  • Bernadett Szabados

  • Julia Choy

  • Francesca Jackson-Spence

  • Thomas Powles

  • Daniel Castellano

  • Begoa P. Valderrama

Medical Centers

  • Bart's Cancer Institute, London, United Kingdom

  • Barts Health NHS Trust, London, United Kingdom

  • Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free National Health Service Trust,, London, United Kingdom

  • Hospital Universitario Doce de Octubre, Madrid, Spain

  • Department of Medical Oncology, Hospital Universitario Virgen del Rocio, Seville, Spain

Locations

  • United Kingdom

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • N/A

Drug/Treatment

  • Enfortumab vedotin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved